151 related articles for article (PubMed ID: 19394967)
1. Inhibition of growth in medullary thyroid cancer cells with histone deacetylase inhibitors and lithium chloride.
Adler JT; Hottinger DG; Kunnimalaiyaan M; Chen H
J Surg Res; 2010 Apr; 159(2):640-4. PubMed ID: 19394967
[TBL] [Abstract][Full Text] [Related]
2. Combination therapy with histone deacetylase inhibitors and lithium chloride: a novel treatment for carcinoid tumors.
Adler JT; Hottinger DG; Kunnimalaiyaan M; Chen H
Ann Surg Oncol; 2009 Feb; 16(2):481-6. PubMed ID: 19030935
[TBL] [Abstract][Full Text] [Related]
3. Histone deacetylase inhibitors upregulate Notch-1 and inhibit growth in pheochromocytoma cells.
Adler JT; Hottinger DG; Kunnimalaiyaan M; Chen H
Surgery; 2008 Dec; 144(6):956-61; discussion 961-2. PubMed ID: 19041003
[TBL] [Abstract][Full Text] [Related]
4. Suberoyl bishydroxamic acid activates notch1 signaling and suppresses tumor progression in an animal model of medullary thyroid carcinoma.
Ning L; Jaskula-Sztul R; Kunnimalaiyaan M; Chen H
Ann Surg Oncol; 2008 Sep; 15(9):2600-5. PubMed ID: 18563491
[TBL] [Abstract][Full Text] [Related]
5. Valproic acid activates Notch1 signaling and induces apoptosis in medullary thyroid cancer cells.
Greenblatt DY; Cayo MA; Adler JT; Ning L; Haymart MR; Kunnimalaiyaan M; Chen H
Ann Surg; 2008 Jun; 247(6):1036-40. PubMed ID: 18520232
[TBL] [Abstract][Full Text] [Related]
6. Suberoyl bis-hydroxamic acid activates Notch-1 signaling and induces apoptosis in medullary thyroid carcinoma cells.
Ning L; Greenblatt DY; Kunnimalaiyaan M; Chen H
Oncologist; 2008 Feb; 13(2):98-104. PubMed ID: 18305053
[TBL] [Abstract][Full Text] [Related]
7. Histone Deacetylase Inhibitors: A Novel Therapeutic Weapon Against Medullary Thyroid Cancer?
Damaskos C; Garmpis N; Valsami S; Spartalis E; Antoniou EA; Tomos P; Karamaroudis S; Zoumpou T; Pergialiotis V; Stergios K; Michaelides C; Kontzoglou K; Perrea D; Nikiteas N; Dimitroulis D
Anticancer Res; 2016 Oct; 36(10):5019-5024. PubMed ID: 27798860
[TBL] [Abstract][Full Text] [Related]
8. Synergistic neuroprotective effects of lithium and valproic acid or other histone deacetylase inhibitors in neurons: roles of glycogen synthase kinase-3 inhibition.
Leng Y; Liang MH; Ren M; Marinova Z; Leeds P; Chuang DM
J Neurosci; 2008 Mar; 28(10):2576-88. PubMed ID: 18322101
[TBL] [Abstract][Full Text] [Related]
9. Notch1 mediates growth suppression of papillary and follicular thyroid cancer cells by histone deacetylase inhibitors.
Xiao X; Ning L; Chen H
Mol Cancer Ther; 2009 Feb; 8(2):350-6. PubMed ID: 19190121
[TBL] [Abstract][Full Text] [Related]
10. Synergistic effects of GSK-3β and HDAC inhibitors in intracerebroventricular streptozotocin-induced cognitive deficits in rats.
Sharma S; Taliyan R
Naunyn Schmiedebergs Arch Pharmacol; 2015 Mar; 388(3):337-49. PubMed ID: 25547373
[TBL] [Abstract][Full Text] [Related]
11. Tautomycetin and tautomycin suppress the growth of medullary thyroid cancer cells via inhibition of glycogen synthase kinase-3beta.
Adler JT; Cook M; Luo Y; Pitt SC; Ju J; Li W; Shen B; Kunnimalaiyaan M; Chen H
Mol Cancer Ther; 2009 Apr; 8(4):914-20. PubMed ID: 19372564
[TBL] [Abstract][Full Text] [Related]
12. Inactivation of glycogen synthase kinase-3beta, a downstream target of the raf-1 pathway, is associated with growth suppression in medullary thyroid cancer cells.
Kunnimalaiyaan M; Vaccaro AM; Ndiaye MA; Chen H
Mol Cancer Ther; 2007 Mar; 6(3):1151-8. PubMed ID: 17363508
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of the NOTCH1 intracellular domain inhibits cell proliferation and alters the neuroendocrine phenotype of medullary thyroid cancer cells.
Kunnimalaiyaan M; Vaccaro AM; Ndiaye MA; Chen H
J Biol Chem; 2006 Dec; 281(52):39819-30. PubMed ID: 17090547
[TBL] [Abstract][Full Text] [Related]
14. Combined lithium and valproate treatment delays disease onset, reduces neurological deficits and prolongs survival in an amyotrophic lateral sclerosis mouse model.
Feng HL; Leng Y; Ma CH; Zhang J; Ren M; Chuang DM
Neuroscience; 2008 Aug; 155(3):567-72. PubMed ID: 18640245
[TBL] [Abstract][Full Text] [Related]
15. Suberoyl bis-hydroxamic acid activates Notch1 signaling and induces apoptosis in anaplastic thyroid carcinoma through p53.
Li J; Zheng X; Gao M; Zhao J; Li Y; Meng X; Qian B; Li J
Oncol Rep; 2017 Jan; 37(1):458-464. PubMed ID: 28004113
[TBL] [Abstract][Full Text] [Related]
16. Expression of the active Notch1 decreases MTC tumor growth in vivo.
Jaskula-Sztul R; Pisarnturakit P; Landowski M; Chen H; Kunnimalaiyaan M
J Surg Res; 2011 Nov; 171(1):23-7. PubMed ID: 21571316
[TBL] [Abstract][Full Text] [Related]
17. Notch1 signaling is irresponsible to the anti-leukemic effect of HDACis in B-ALL Nalm-6 cells.
Shao N; Ma D; Wang J; Lu T; Guo Y; Ji C
Ann Hematol; 2013 Jan; 92(1):33-9. PubMed ID: 22968660
[TBL] [Abstract][Full Text] [Related]
18. Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer.
Zhang L; Zhang Y; Mehta A; Boufraqech M; Davis S; Wang J; Tian Z; Yu Z; Boxer MB; Kiefer JA; Copland JA; Smallridge RC; Li Z; Shen M; Kebebew E
Oncotarget; 2015 Apr; 6(11):9073-85. PubMed ID: 25940539
[TBL] [Abstract][Full Text] [Related]
19. The mood stabilizer valproate activates human FGF1 gene promoter through inhibiting HDAC and GSK-3 activities.
Kao CY; Hsu YC; Liu JW; Lee DC; Chung YF; Chiu IM
J Neurochem; 2013 Jul; 126(1):4-18. PubMed ID: 23647222
[TBL] [Abstract][Full Text] [Related]
20. Modulation of matrix metalloproteinase activity in human thyroid cancer cell lines using demethylating agents and histone deacetylase inhibitors.
Mitmaker EJ; Griff NJ; Grogan RH; Sarkar R; Kebebew E; Duh QY; Clark OH; Shen WT
Surgery; 2011 Apr; 149(4):504-11. PubMed ID: 21193210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
